Several analysts have recently updated their ratings and price targets for Kardigan (NASDAQ: KARD):
- 7/15/2026 – Kardigan was upgraded by Zacks Research to “hold”.
- 7/13/2026 – Kardigan is now covered by TD Cowen. They set a “buy” rating and a $46.00 price target on the stock.
- 7/13/2026 – Kardigan is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $40.00 price target on the stock.
- 7/13/2026 – Kardigan is now covered by TD Cowen. They set a “buy” rating and a $46.00 price target on the stock.
- 7/13/2026 – Kardigan is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $40.00 price target on the stock.
- 7/13/2026 – Kardigan is now covered by Leerink Partners. They set an “outperform” rating and a $37.00 price target on the stock.
- 7/13/2026 – Kardigan is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $51.00 price target on the stock.
- 6/27/2026 – Kardigan was upgraded by Wall Street Zen to “hold”.
Insider Transactions at Kardigan
In related news, Director Paul L. Berns bought 1,250,000 shares of the stock in a transaction dated Monday, June 22nd. The shares were purchased at an average price of $16.00 per share, for a total transaction of $20,000,000.00. Following the completion of the purchase, the director directly owned 15,042,035 shares of the company’s stock, valued at $240,672,560. This represents a 9.06% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arch Venture Partners Xiii, Ll bought 1,250,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average cost of $16.00 per share, for a total transaction of $20,000,000.00. Following the completion of the acquisition, the director owned 15,042,035 shares of the company’s stock, valued at $240,672,560. This trade represents a 9.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.
Kardigan, Inc is a healthcare company in the Biotechnology industry.
Featured Stories
- Five stocks we like better than Kardigan
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Kardigan Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kardigan Inc and related companies with MarketBeat.com's FREE daily email newsletter.
